BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
4.770
-0.120 (-2.45%)
At close: Sep 18, 2026, 4:00 PM EDT
4.834
+0.064 (1.34%)
After-hours: Sep 18, 2026, 7:30 PM EDT
BBOT Stock Forecast
BBOT's stock price has decreased by -55.79% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 12 analysts polled by S&P Global, BBOT stock has a consensus rating of "Strong Buy" and an average price target of $24.73. The average 1-year stock price forecast is 418.45% higher than the current stock price, while the lowest is $15 (+214.47%) and the highest is $50 (+948.22%).
Price Target: $24.73 (+418.45%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BBOT stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $27 → $25 | Buy | Maintains | $27 → $25 | +424.11% | Sep 18, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $25 | Buy | Maintains | $25 | +424.11% | Sep 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $21 | Buy | Maintains | $21 | +340.25% | Sep 9, 2026 |
| Raymond James | Raymond James | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +361.22% | Sep 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.85
from -4.30
EPS Next Year
-2.72
from -2.85
EPS and Forward PE are based on non-GAAP adjusted numbers.